

RNS: RELEASE

30 June 2023

ImmuPharma PLC
("ImmuPharma" or the "Company")

2023 RESULT OF ANNUAL GENERAL MEETING – ALL RESOLUTIONS PASSED

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, held its AGM earlier today. The Company is pleased to announce that all resolutions were duly passed, details of which are contained in the table below.

Resolution	For	% For	Against	% Against	Withheld
1. To receive the accounts of the Company for the year ended 31 December 2022 together with the reports thereon of the directors and auditors of the Company	52,114,317	99.08	482,400	0.92	49,317
2. To re-appoint Dr Sanjeev Pandya as a director of the Company	47,601,452	90.55	4,964,842	9.44	79,740
3. To re-appoint CLA Evelyn Partners Limited as Auditor of the Company	52,084,178	99.08	482,400	0.92	79,456
4. That the Directors be authorised for the purpose of Section 551 of the Companies Act 2006 (the "Act") to allot shares on the basis as set out in the Notice of Meeting	51,003,388	98.86	585,640	1.14	1,057,006
5. That the Company may send or supply documents or information to members by making them available on a website or other electronic means.	52,115,217	99.08	484,400	0.92	46,417

SPECIAL RESOLUTION					
6. That, subject to the passing of Resolution 4 the directors be and they are hereby empowered pursuant to section 571 of the Act to allot equity securities (as defined in section 560 of the Act).	51,013,053	99.88	575,975	1.12	1,057,006

As at the date of the AGM, the number of issued ordinary shares of the Company was 333,403,115 shares, which was the total number of shares entitling the holders to attend and vote for or against all resolutions. In accordance with the Company's Articles of Association, every member has one vote for every share held. Votes withheld are not votes in law and have not been counted in the calculation of the proportion of vote "for" or "against" a resolution. Proxy appointments which gave discretion to the Chairman have been included in the "for" total.

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation no 596/2014 which is part of English law by virtue of the European (withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

Ends

For further information please contact:

ImmuPharma PLC (www.immupharma.com)	+44 (0) 207 206 2650
Tim McCarthy, Chairman and Chief Executive Officer	
Lisa Baderoon, Head of Investor Relations & Non-Executive Director	+ 44 (0) 7721 413496
SPARK Advisory Partners Limited (NOMAD)	+44 (0) 203 368 3550
Neil Baldwin	
Stanford Capital Partners (Joint Broker)	+44 (0) 20 3650 3650
Patrick Claridge, John Howes, Bob Pountney	
SI Capital (Joint Broker)	+44 (0) 1483 413500
Nick Emerson	

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

For additional information about ImmuPharma please visit www.immupharma.co.uk

ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.